DPP4 Inhibitors: a new approach in diabetes treatment
- 18 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Advances in Therapy
- Vol. 25 (7), 627-643
- https://doi.org/10.1007/s12325-008-0076-1
Abstract
The role of dipeptidyl peptidase-IV (DPP4) as both a regulatory enzyme and a signalling factor has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation of insulin secretion, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA1c) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development. This review article focuses on the two leading agents of this category (sitagliptin and vildagliptin), providing an overview of their function along with the latest data regarding their clinical efficacy as antidiabetic agents.This publication has 63 references indexed in Scilit:
- Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia*Diabetes, Obesity and Metabolism, 2008
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurrent Medical Research and Opinion, 2007
- Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetesExpert Opinion on Investigational Drugs, 2007
- The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy VolunteersClinical Pharmacokinetics, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- DPP-4 inhibitors and their potential role in the management of type 2 diabetesInternational Journal of Clinical Practice, 2006
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteersClinical Therapeutics, 2006
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumJBIC Journal of Biological Inorganic Chemistry, 1993